Within the next two weeks, Novo Nordisk is expected to announce the results of perhaps the most ambitious studies yet of its blockbuster GLP-1 drug semaglutide — whether the medicine can help slow the progression of Alzheimer’s disease.

The Danish company has repeatedly stressed that these are risky studies, since there hasn’t yet been definitive proof that this class of drugs, which has transformed the treatment of obesity and diabetes, can also help patients with the devastating neurological disease.

But the drugmaker still appears to be quietly preparing for the possibility that it may soon be able to add Alzheimer’s to the list of approved indications for semaglutide, marketed as Ozempic and Wegovy. Novo posted job openings just a few days ago for at least four positions around the w

See Full Page